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351 Effectiveness of omalizumab for treatment of allergic
bronchopulmonary aspergillosis (ABPA) among children and
adolescents with cystic ﬁbrosis
E. Hatziagorou1, V. Avramidou1, S. Botskarieva1, F. Kirvasillis1, A. Mavroudi1,
J.N. Tsanakas1. 1Hippokration Hospital, Aristotle University of Thessaloniki,
Paediatric Pulmonology Unit, 3rd Paediatric Dept, Thessaloniki, Greece
Background: Allergic bronchopulmonary aspergillosis (ABPA) is a common com-
plication among patients with CF that produces signiﬁcant respiratory morbidity.
Standard therapy for ABPA includes systemic corticosteroids for a prolonged
period of time with potentially severe side effects and use of antifungal agents.
Omalizumab is a humanized monoclonal antibody directed against IgE that prevents
its binding to receptors on effector cells. It has been shown to be effective in
improving asthma control in patients with a strong allergic component. Recently,
sporadic reports of omalizumab use against ABPA have been reported.
Methods: We present our long term experience of omalizumab in three children
with CF and ABPA who were steroid dependent.
Results: Five (3.4%) out of 148 children and adolescents with CF followed in
our Unit over a seven year period, developed ABPA (75% females, mean age at
start of therapy 14.3 years). Omalizumab was given to 3 of them (2 males, mean
age 17.1 years, mean FEV1 35%). All three were already experiencing signiﬁcant
side effects from chronic steroid therapy (invasive aspergillosis, diabetes mellitus,
depression, relapse of ABPA and severe osteoporosis) and received regular antifugal
therapy. Omalizumab treatment was given for a period of 12−18 months. Oral
steroids were gradually stopped. Omalizumab resulted in signiﬁcant improvement
of respiratory symptoms and lung function (mean FEV1 52%, p: 0.01).
Conclusion: According to our results in a small number of patients, omalizumab has
a signiﬁcant potential as a strategy to control ABPA in steroid dependent patients.
However, more studies are needed to conﬁrm these ﬁndings.
352 Minocycline in CF patients: beware of myopericarditis!
M. Mittaine1, E. Mas1, J.-L. Rittie´1, Y. Dulac2, F. Bre´mont1. 1CRCM Pe´diatrique,
Hoˆpital des Enfants, Toulouse, France; 2Cardiologie Pe´diatrique, Hoˆpital des
Enfants, Toulouse, France
Introduction: Minocycline is used to treat pulmonary exacerbation of CF patients.
Despite its usefulness, it should be used with caution because of potentially serious
adverse events.
Case report: 2 CF paediatrics patients suffered cardiac complications after admin-
istration of minocycline.
Patient 1, 17 years old, colonised by Alcaligenes xylosoxidans, had an alternative
antibioprophylaxis (1 month minocycline 100mg/day alternating with 1 month
sulfamethoxazole–trimethoprim) for 3 years. He presented fever and back pain,
so minocycline posology was raised to 200mg/day during 8 days. 2 weeks later he
had dry cough, asthenia, muscular pain. 6 weeks later, a pericardial effusion was
discovered on a systematic CT and conﬁrmed on echocardiography. All aetiologies
were ruled out except adverse effect of minocycline. An anti-inﬂammatory treatment
by naproxen was given during 1 month. The pericarditis resolved totally within this
month.
Patient 2, 11 years old, colonised by Staphylococcus, had pulmonary exacerbation
treated by minocycline 100mg/day during 1 month. 4 months later, a malaise
conducted to the diagnosis of moderate dilated cardiomyopathy, treated from then
on by losartan. Minocycline was not suspected at this time. 8 months later, a new
treatment by minocycline was rapidly followed by fever, hypereosinophilia and
pleural effusion. Minocycline was then suspected and discharged.
Conclusion: As it has been shown in patients suffering acnea, minocycline can
be responsible for serious cardiac events in CF patients. The French Drug Agency
recently limited the use of this drug to documented infections resistant to other
drugs available per os.
353 Achromobacter xylosoxidans in cystic ﬁbrosis: indirect
patient-to-patient contact can lead to cross-infection
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Background: The prevalence of chronic A. xylosoxidans (AX) lung infection in
cystic ﬁbrosis (CF) patients is increasing. Several studies have shown cross infection
in patients with close, direct contact (siblings).
We present 2 cases of CF patients with new acquisition of AX lung infection after
indirect contact to patients with chronic AX lung infection.
Methods: The indirect contact between patients is described and pulsed ﬁeld gel
electrophoresis (PFGE) done on isolates from individual patients.
Case 1: A 6-year-old girl (A) with CF became close friends with the little sisters
of a 15 years old CF patient (B) with chronic AX lung infection. A came in the
home of B, but the 2 patients did not have direct contact and did not even stay in
the same room simultaneously. At the age of 8 years, A ﬁrst had AX in sputum
samples after a period of clinical instability with decrease in BMI and increased
sputum production and a 50% reduction in FEV1.
Case 2: A 13-year-old boy (C) with CF went on a (non CF) skiing vacation. In the
same group was a 22-years-old CF male (D) with chronic pulmonary AX infection.
C and D ate in the same room, but slept in separate rooms and did not have close
contact. Six months after the vacation, C experienced clinical deterioration with a
rapid decrease in FEV1 and nutritional status. BAL was performed and revealed
AX infection.
PFGE on isolates showed identical strains from A and B and from C and D.
Conclusion: AX cross infection between CF patients is possible, even without
direct patient-to-patient contact, and after few days of indirect contact. Long-term
follow-up is recommended, since AX was not found until several months after
exposure.
354 Trichosporon asahii, the ﬁrst report of colonisation with this new
potential pathogen, including therapeutic considerations
P. Meyer1. 1Skane University Hospital, Pediatrics, Lund, Sweden
Objective: A PubMed search for the yeast fungus T. asahii and CF was negative.
A case has been reported with fatal pneumonia caused by T. mycotoxinivorans in
a non-transplanted but steroid-treated CF patient. Trichosporon asahii infections
are rare but increasingly recognized as cause of systemic and invasive illness in
immunocompromized patients, thus potentially pathogenic and treatment should be
considered.
Methods: A 17-year-old female with CF as the only risk factor for opportunistic
lung infection. August 2011 she was clinically stable with normal BMI and FEV1
>93% of predicted value. But chronically infected with Staphylococcus aureus
and after having been “free from” she had 2 sp-cultures positive for Aspergillus
fumigatus and started treatment with posaconazole. Sp-culture after 2 month
treatment was without A. fumigatus, but with T. asahii. Another two monthly
sp-culture was positive for T. asahii. Chest X-ray, FEV1 and symptoms were
stable. Due to the potentially severe outcome we started treatment in December
with ﬂuconazole, not voriconazole due to risk of side-effects on holidays. Control
sp-cultures not yet done.
Conclusions:Motivation for treating colonisation with T. asahii in a stable teenager
is the risk for dissemination and deterioration. If not eradicated by ﬂuconazol, and
especially if signs of invasion, treatment with voriconazole will be started, ev as
inhalation (nebulized), trying to avoid side effects.
